Please login to the form below

Not currently logged in
Email:
Password:

Amgen buys US rights to Servier’s Procoralan

Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe

Servier Procoralan

Amgen and Servier have completed a product-swapping collaboration involving several cardiovascular products.

The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has obtained US rights to for an upfront fee of $50m plus undisclosed future milestones and royalties on sales.

The drug is currently unavailable in the US, although it is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates.

US-based Amgen will be looking to market the drug for similar use in the US and will handle regulatory filings the US Food and Drug Administration (FDA).

In addition, Amgen also has the exclusive option to develop and commercialise Servier's investigational molecule, S38844, for cardiovascular diseases in the US,

The drug is currently being investigated in phase II studies for the treatment of heart failure.

In return, Servier obtained an exclusive option to commercialise Amgen's omecamtiv mecarbil in Europe.

The investigational drug is an activator of cardiac myosin and is being tested for use in heart failure patients with systolic dysfunction.

It is the most advanced drug candidate coming out of Amgen's collaboration with Cytokinetics signed in 2006.

“A critical unmet medical need remains for patients who don't respond adequately to current available therapies for heart failure and angina,” said Amgen's executive VP of R&D Dr Sean Harper at the time the deal was first announced last month.

“Ivabradine, an If inhibitor, offers a novel alternative approach for patients with elevated heart rates.”

Article by
Thomas Meek

14th August 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics